Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.


a platinum coordination compound whose main mode of action resembles that of alkylating agents with production of cross links between the two strands of DNA in the double helix so that DNA cannot be replicated and the cells cannot divide. It is used as an antineoplastic agent in the treatment of metastatic tumors of the testis, ovary, bladder, and head and neck. It can cause serious damage to the kidney, eighth cranial nerve, gastrointestinal tract, and bone marrow, can upset metabolic processes, and can produce hypocalcemia and hypomagnesemia. Called also DDP or cis-DDP.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Platinex (UK)

Pharmacologic class: Alkylating agent, platinum coordination complex

Therapeutic class: Antineoplastic

Pregnancy risk category D

FDA Box Warning

• Give under supervision of physician experienced in cancer chemotherapy, in facility with adequate diagnostic and treatment resources.

• Drug may cause severe cumulative renal toxicity. Other major dose-related toxicities are myelosuppression, nausea, and vomiting.

• Drug may lead to significant ototoxicity (which may be more pronounced in children), high-frequency hearing loss, and deafness.

• Anaphylactic-like reactions may occur within minutes of administration.

• Use caution to prevent inadvertent overdose. Doses above 100 mg/m2/cycle once every 3 to 4 weeks are rarely used. Avoid inadvertent overdose stemming from confusion with Paraplatin (carboplatin) or failure to differentiate daily doses from total dose per cycle.


Inhibits DNA synthesis by causing intrastrand and interstrand cross-linking of DNA


Injection: 1 mg/ml in 50-mg and 100-mg multidose vials

Indications and dosages

Metastatic testicular tumors

Adults: 20 mg/m2 I.V. daily for 5 days/cycle, repeated q 3 to 4 weeks

Metastatic ovarian cancer

Adults: 75 to 100 mg/m2 I.V., repeated q 4 weeks in combination with cyclophosphamide; or 100 mg/m2 q 4 weeks as a single agent

Advanced bladder cancer

Adults: 50 to 70 mg/m2 I.V. q 3 to 4 weeks as a single agent; dosage depends on whether patient has undergone radiation or chemotherapy.

Off-label uses

• Cervical cancer

• Squamous cell carcinoma


• Hypersensitivity to drug or other platinum-containing compounds

• Severe impairment of renal function

• Severe myelosuppression

• Hearing impairment

• Pregnancy or breastfeeding


Use cautiously in:

• mild to moderate renal impairment, active infection, myelosuppression, chronic debilitating illness, heart failure, electrolyte abnormalities

• females of childbearing age.


• Prepare drug with equipment that doesn't contain aluminum.

• Give 2 L of I.V. fluids, as prescribed, 8 to 12 hours before drug infusion to help prevent toxicity.

• Dilute each dose in 2 L of dextrose 5% in 1/4 or 1/2 saline solution or 0.9% normal saline solution. Do not use dextrose 5% in water.

• Infuse each liter over 3 to 4 hours to minimize toxicity. In well-hydrated patients with good renal function, infusions of 100 to 500 ml may be given over 30 minutes.

• Follow facility policy for handling and disposal of antineoplastics.

If solution contacts skin, wash immediately and thoroughly with soap and water. If solution contacts mucosa, flush with water immediately.

• Protect drug from light.

Adverse reactions

CNS: malaise, weakness, seizures

EENT: ototoxicity, tinnitus

GI: severe nausea, vomiting, diarrhea

GU: sterility, nephrotoxicity

Hematologic: anemia, leukopenia, thrombocytopenia

Hepatic: hepatotoxicity

Metabolic: hypocalcemia, hypokalemia, hypomagnesemia, hyperuricemia

Skin: alopecia

Other: phlebitis at I.V. site, anaphylaxis


Drug-drug. Amphotericin B, loop diuretics: increased risk of hypokalemia and hypomagnesemia

Antineoplastics: additive bone marrow depression

Live-virus vaccines: decreased antibody response to vaccine, increased risk of adverse reactions

Nephrotoxic drugs (such as aminoglycosides): additive nephrotoxicity

Ototoxic drugs (such as loop diuretics): additive ototoxicity

Phenytoin: reduced phenytoin blood level

Drug-diagnostic tests. Aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, uric acid: increased levels

Calcium, magnesium, phosphate, potassium, sodium: decreased levels
Coombs' test: positive result

Patient monitoring

• Before starting therapy and before each subsequent dose, assess renal function test results and CBC with white cell differential.

• Monitor neurologic status, hepatic enzyme and uric acid levels, and audiogram results.

• Monitor urine output closely.

Patient teaching

• Instruct patient to drink 8 oz of water every hour while awake.

Advise patient to promptly report bleeding, bruising, hearing loss, yellowing of skin or eyes, decreased urine output, or suspected infection.

• Tell patient that drug may cause hair loss.

• Instruct female patient to use reliable contraception; drug can harm fetus.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(sĭs-plăt′n, -plā′tn)
A platinum-containing chemotherapeutic drug, Cl2H6N2Pt, used in the treatment of metastatic ovarian or testicular cancers and advanced bladder cancer. Also called cisplatinum.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A chemotherapeutic that forms covalent bonds and crosslinks with DNA, which is used for head and neck, ovarian, testicular, and bladder cancers and lymphomas.

Adverse effects
Nephrotoxicity, nausea, sensory neuropathy.

Management for adverse effects
• Nephrotoxicity: adequate hydration to maintain renal flow and high chloride concentration.
• Nausea: ondansetron, a selective antagonist of serotonin S3 receptors.
• Neuropathy: amifostine, growth factors, glutathione, Org 2766, acetyl-L-carnitine, vitamin E have all been tried; per Cochrane review, none proved effective; more studies are needed.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.


Cis-platinum, diaminedichloride, Platinol A chemotherapeutic that forms covalent bonds and crosslinks with DNA, which is used for head & neck, ovarian, testicular, bladder CAs, lymphomas Adverse effects Nephrotoxicity, nausea, neurotoxicity
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.


An anticancer drug. Like any drug that damages cells it has side effects. Cisplatin can cause progressive kidney impairment. The drug is on the WHO official list.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Patient discussion about cisplatin

Q. Is pervasive developmental disorder (PDD) or autism is fatal……what exactly it is……?

A. Autism is not fatal in its symptom and progression but it can become fatal as it does impair normal physiological function it CAN BE a fatal condition. It’s a group of illness which involves delays in the development of basic skills. It happens to children below age 3. It affects the child`s ability to communicate and interact. Autism affected children are also found to be mentally retarded.

Q. I was at my colleague's home and one of his kids kept talking to herself he said that she has PDD. i later asked my wife about it and she said she thinks it's a type of autism. but other than talking to herself the girl seemed perfectly normal. so is PDD a light version of autism?

A. I didn't really understand everything in this web page, but I think I get the big picture. Thanx

Q. What resources are available in Seattle, Washington to help with an autistic child?

A. i miss Seattle... here is a link to "Autism Spectrum Treatment and Research (ASTAR) Center". a well know establishment:

More discussions about cisplatin
This content is provided by iMedix and is subject to iMedix Terms. The Questions and Answers are not endorsed or recommended and are made available by patients, not doctors.
References in periodicals archive ?
(a) The multicompartmental pharmacokinetic model and (b) Patlak plot both indicated that Ki was significantly increased after cisplatin administration in Groups A (Cis 2 mg/kg) and B (Cis 4 mg/kg), but there was no difference in Group C (Cis 4 mg/kg + SAHA 300 mg/kg).
Elson et al., "A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study," Journal of Clinical Oncology, vol.
Sancar, "HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease," Proceedings of the National Academy of Sciences, vol.
Seven groups are formed in the study, concurrently chemotherapy (cisplatin) +RT+/- gefitinib/placebo and later on as adjuvant gefitinib or placebo treatment are applied to the patients.
Though Cisplatin containing regimens remain the standard of care in MGCT, Carboplatin may be used and a fair option in special scenarios likes the reported case.
Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation.
Negative neurons in spiral ganglions and strong TUNEL-positive neurons in cisplatin, G.
This indicated that LINC00261 overexpression decreased cisplatin resistance of SW480/ DDP cells.
Results remained consistent when restricting analysis to those who received both etoposide and cisplatin as initial therapy.
An established combination consists of Cisplatin Injection and cyclophosphamide.
The aim of current study was to determine the development of cisplatin induced oxidative stress followed by evaluation of hepatotoxicity in laboratory animals.